Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Smoking Treatment of Prisoners (STOP)

This study has been completed.
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00110630
First received: May 11, 2005
Last updated: September 29, 2008
Last verified: September 2008

May 11, 2005
September 29, 2008
June 2005
September 2007   (final data collection date for primary outcome measure)
smoking cessation [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00110630 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Smoking Treatment of Prisoners
Smoking Treatment of Prisoners: Project "STOP"

The purpose of this study is to determine the efficacy of a 10-week smoking cessation therapy combined with NicoDerm CQ for smoking cessation among female prisoners.

This is a randomized controlled trial utilizing a wait-list control group to examine 10-week group therapy and nicotine replacement compared to wait-list for smoking cessation among female prisoners.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Masking: Open Label
Primary Purpose: Treatment
  • Tobacco Use Cessation
  • Tobacco Use Disorder
Behavioral: 10-week smoking cessation group therapy combined with NicoDerm CQ
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
0
September 2007
September 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • 1) current smoker and (2) seeking group treatment to quit smoking.

Exclusion Criteria:

  • (1) non-english speaking, (2) housed in segregation, (3) presence of active, severe mental illness as defined by active psychosis, manic episode, or imminently suicidal/homicidal, (4) mental retardation such that they cannot provide informed consent, and (5) due to be released or transferred to another facility within the next year.
Female
18 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00110630
NIDA-15774-2, K23-15774-2
Yes
Karen Cropsey, Univeristy of Alabama at Birmingham
National Institute on Drug Abuse (NIDA)
GlaxoSmithKline
Principal Investigator: Karen Cropsey, Ph.D. Virginia Commonwealth University
National Institute on Drug Abuse (NIDA)
September 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP